NCT01511419 is a Phase 1 clinical trial of LAIV H7N3 in Influenza, sponsored by PATH.

Who is sponsoring NCT01511419?

NCT01511419 is sponsored by PATH.

What drugs are being tested in NCT01511419?

Interventions in NCT01511419: LAIV H7N3, placebo.

What condition does NCT01511419 study?

NCT01511419 studies Influenza, Avian Influenza.

Is NCT01511419 still recruiting?

NCT01511419 is currently completed. Last updated 22 January 2019.

Are results published for NCT01511419?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-01-22 · How we verify

NCT01511419

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine

Completed Phase 1 Results posted Last updated 22 January 2019

What this trial tests

Phase 1 trial testing LAIV H7N3 in Influenza in 40 participants. Completed in 1 July 2012.

Timeline

1 April 2012

Primary endpoint
1 June 2012

1 July 2012

Quick facts

Lead sponsor	PATH
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	40
Start date	1 April 2012
Primary completion	1 June 2012
Estimated completion	1 July 2012
Sites	1 location across Russia

Drugs / interventions tested

LAIV H7N3 — full drug profile →
placebo

Conditions studied

Influenza — all drugs for Influenza →
Avian Influenza — all drugs for Avian Influenza →

Sponsor

PATH — full company profile →

Who can join

Adults 18 to 49, any sex, with Influenza or Avian Influenza. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants With Immediate Reactions
Time frame: 2 hours post-administration on Days 0 and 28
From administration of any dose, immediate reaction measured as observed by study staff or reported by the subject to study staff in case of an anaphylactic reaction.
Adverse Events Associated With Intranasal Vaccination
Time frame: Greater than 2 hours through 7 days following any dose
From solicited local and systemic reactions
All Other Adverse Events
Time frame: 7 days following any dose
Including unsolicited events and abnormal laboratory findings
Participants With Serious Adverse Events (SAEs)
Time frame: Within 4 weeks of receipt of any dose
Including abnormal laboratory findings

Sponsor's own description

The study hypothesis is that two doses of cold-adapted, live monovalent A/17/mallard/Netherlands/00/95 (H7N3) influenza vaccine will be safe and immunogenic in healthy adults.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Other PATH trials

Trials by the same sponsor.

NCT06895486 — Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation · Phase 2 · recruiting
NCT06129916 — Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB · not yet recruiting
NCT06879327 — Infant Malaria Vaccine Schedule Optimization · Phase 2 · recruiting
NCT06137664 — Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines · Phase 1, PHASE2 · recruiting
NCT05758506 — Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01511419 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PATH
Last refreshed: 22 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01511419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing